BOLERO-2 PMCID and abstract PFS sentence directly verified from PMC

BOLERO-2 主文的 PMCID 与摘要原句已在公开全文中直接核对

''结论''
BOLERO-2 主文（final progression-free survival analysis）的公开全文页与 Europe PMC 结构化记录一致给出：

- PMID: ''24158787''
- PMCID: ''PMC3898123''
- DOI: ''10.1007/s12325-013-0060-1''
- 题名: ''Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.''

''摘要原句（Results）''
"Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2 months, respectively; hazard ratio = 0.45 (95% confidence interval 0.38-0.54); log-rank P < 0.0001; central review: 11.0 versus 4.1 months, respectively; hazard ratio = 0.38 (95% confidence interval 0.31-0.48); log-rank P < 0.0001]..."

''可复现核对路径''
1. PMC 页面直接显示 PMCID：https://pmc.ncbi.nlm.nih.gov/articles/PMC3898123/
2. Europe PMC 结构化 JSON 同时返回 PMID / PMCID / DOI / abstractText：https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24158787%20SRC:MED&amp;format=json&amp;resultType=core

''审稿人式提醒''
- 这一条不应再依赖二手摘要或转引；PMCID 必须从主文页/结构化索引页直取。
- 页面提示该文有 correction/erratum 记录，但不影响本轮所核对的书目信息与摘要主结果句。